SynthesisIrish journal of medical science2018
The role of liver resection in patients with metastatic breast cancer: a systematic review examining the survival impact.
Synthesis in Irish journal of medical science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Breast cancer liver metastases: systematic review and time to event meta-analysis with comparison between available treatments.Annals of the Royal College of Surgeons of England · 2023Pooled it
- [Non-colorectal liver metastases-Indications and treatment approach].Chirurgie (Heidelberg, Germany) · 2026Review
- Different risk and prognostic factors for liver metastasis of breast cancer patients withFrontiers in oncology · 2023Article
- Review
- Review
- Clinical Outcome of Patients Submitted to Liver Resection in the Context of Metastatic Breast Cancer: A Study of a Tertiary Hospital Center.Medicines (Basel, Switzerland) · 2021Article
- Breast cancer liver metastasis: current and future treatment approaches.Clinical & experimental metastasis · 2021Review
- Risk Factors and Survival of Patients With Liver Metastases at Initial Metastatic Breast Cancer Diagnosis in Han Population.Frontiers in oncology · 2021Article
- Renewed considerations on the utility (or the futility) of hepatic resections for breast cancer liver metastases.Hepatobiliary surgery and nutrition · 2021Review
- Surgical therapy for breast cancer liver metastases.Translational cancer research · 2020Review
- A positive conversion in hormone receptor and HER2 status might have an impact on survival after liver resection for breast cancer metastases.Irish journal of medical science · 2018Article
- [Role of visceral surgery in oligometastases of non-gastrointestinal tumors].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionApproximately 10% of breast cancer patients will present with solid organ metastases, while up to 30% will develop metastatic disease during their treatment course. Liver metastases are usually treated with systemic chemotherapy. Although colorectal liver metastases are routinely resected, this is not yet the standard of care for breast cancer-related liver metastases. This review examines the evidence for resection of breast cancer-related liver metastases.
methodsA systematic review identified 25 articles for inclusion, 12 papers concerning patients with isolated liver metastases, and 13 papers concerning patients with extrahepatic metastases. Data from 1080 patients were included.
resultsTwo hundred eighty patients underwent hepatic resections for breast cancer-associated metastases with no extrahepatic metastases. Reported 5-year survival ranged from 24.6 to 78%. Median overall survival ranged from 29.5 to 116 months. For patients with oligometastatic disease undergoing resection, 5-year survival ranged from 21 to 57%, with median overall survival ranging from 32 to 58 months. Reported 30-day morbidity ranged from 14 to 42% for isolated and multiple metastases.
conclusionHepatic resection can be considered in the management of breast cancer patients with isolated liver metastases as well as those with oligometastatic disease.
Indexed as
Identifiers
29392651What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.